WC
NMRA icon

Wexford Capital’s Neumora Therapeutics NMRA Stock Holding History

Wexford Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77,879
Closed -$77.9K – 297
2025
Q1 		$77.9K Sell
77,879
-174,243
-69% -$298K 0.02% 208
2024
Q4 		$2.67M Buy
252,122
+34,243
+16% +$410K 0.43% 37
2024
Q3 		$2.88M Buy
217,879
+103,285
+90% +$1.2M 0.69% 42
2024
Q2 		$1.13M Buy
114,594
+85,421
+293% +$884K 0.29% 56
2024
Q1 		$401K Buy
+29,173
New +$472K 0.08% 146

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wexford Capital's NMRA Position: Q2 2025 in Review

Wexford Capital sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 77,879 shares — an estimated $77.9K sold.

Wexford Capital first reported a position in NMRA in Q1 2024 and held it in 5 quarters. The position peaked at $2.88M in Q3 2024. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • Wexford Capital reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wexford Capital sold 77,879 Neumora Therapeutics shares in Q2 2025, an estimated $77.9K.
  • Wexford Capital first reported a position in Neumora Therapeutics in Q1 2024 and held it in 5 quarters.
  • Wexford Capital's Neumora Therapeutics position peaked at $2.88M in Q3 2024.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.